导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | 5.93% | 1179/4762 |
| 近一周 | -0.93% | 1404/5451 |
| 近一月 | -3.29% | 2339/5408 |
| 近一季 | -7.62% | 2892/5218 |
| 近半年 | -3.08% | 2378/4907 |
| 近一年 | 11.32% | 1031/4387 |
| 近两年 | 84.27% | 793/2950 |
| 近三年 | 49.54% | 565/2249 |
| 成立以来 | 100.90% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
2.22% 1007/4961 |
18.81% 1343/5312 |
- - |
- - |
| 2025 | 32.68% 1167/4813 |
2.39% 1387/3635 |
2.11% 1860/4076 |
24.69% 1444/4524 |
1.78% 1223/4813 |
| 2024 | 11.09% 1346/3463 |
-2.08% 1315/2808 |
-5.01% 1619/3014 |
16.45% 1453/3129 |
2.56% 933/3463 |
| 2023 | -4.27% 673/2656 |
7.76% 525/2280 |
-3.60% 841/2385 |
-3.96% 1023/2515 |
-4.06% 856/2655 |
| 2022 | -16.58% 495/2207 |
-13.06% 692/1919 |
3.36% 1165/2016 |
-9.86% 322/2113 |
2.99% 792/2208 |
| 2021 | 21.06% 169/1822 |
-0.89% 403/1255 |
10.81% 432/1330 |
5.85% 252/1466 |
4.13% 363/1822 |
| 2020 | 28.81% 553/1250 |
-3.33% 297/1028 |
17.19% 387/1067 |
9.37% 654/1164 |
3.96% 883/1184 |
| 2019 | 29.83% 495/1092 |
31.68% 193/754 |
-9.57% 666/804 |
2.09% 325/850 |
6.79% 549/918 |
| 2018 | - - |
- - |
- - |
- - |
-12.15% 410/691 |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 华泰柏瑞中证500ETF联接C VS. 长安沪深300非周期A(740101) |